Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | CTSA | P10619 | 11/20 | 0.40 |
| ▸ | PTGFR | P43088 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21632028 | 0.82 | ADRB2 (0.35) | LMNA | |
| SCHEMBL22993739 | 0.82 | CTSA (0.45) | CTSAPTGFRMEN1KMT2A | |
| SCHEMBL12490826 | 0.80 | CYP1A2 (0.45) | CYP1A2TSHRKMT2A | |
| SCHEMBL21632156 | 0.79 | CYP2D6 (0.43) | CYP1A2LMNACTSAPTGFRMEN1 | |
| SCHEMBL21708797 | 0.77 | CASP1 (0.33) | CYP1A2TSHRLMNAMEN1KMT2A | |
| SCHEMBL17749160 | 0.75 | FFAR1 (0.47) | CTSAMEN1KMT2A | |
| SCHEMBL5623819 | 0.72 | ADRB2 (0.41) | CYP1A2TSHRLMNAKMT2A | |
| SCHEMBL2456546 | 0.72 | MEN1 (0.58) | CYP1A2TSHRCTSAMEN1KMT2A | |
| SCHEMBL27471230 | 0.72 | CTSA (0.47) | CTSAMEN1KMT2A | |
| SCHEMBL11047144 | 0.70 | AKR1B1 (0.47) | CTSAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11136296-B2 | Substituted N-arylethyl-2-arylquinoline-4-carboxamides and use thereof | BAYER AKTIENGESELLSCHAFT (DE) | 2021-10-05 | — | — | US | disclosed |
| US-20200031775-A1 | SUBSTITUTED N-ARYLETHYL-2-ARYLQUINOLINE-4-CARBOXAMIDES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2020-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200031775-A1 | SUBSTITUTED N-ARYLETHYL-2-ARYLQUINOLINE-4-CARBOXAMIDES AND USE THEREOF | AADAC, NAT1, EPX | CYP1A2 409/4885TSHR 3453/4885LMNA 694/4885 |
| US-11136296-B2 | Substituted N-arylethyl-2-arylquinoline-4-carboxamides and use thereof | AADAC, NAT1, EPX | CYP1A2 409/4885TSHR 3453/4885LMNA 694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.